Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is targeting the next wave of DNA Damage Response (DDR) cancer therapies, moving beyond established PARP inhibitors. The company is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to a BioMedWire editorial, Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology and is positioning itself as an early leader in this novel class of cancer therapeutics.
PNKP (polynucleotide kinase 3'-phosphatase) plays a key role in repairing DNA single-strand breaks and double-strand breaks, making it an attractive target for cancer therapy. ONC010 is designed to inhibit PNKP, thereby disrupting cancer cells' ability to repair DNA damage and leading to cell death. The company highlighted preclinical data showing that ONC010 more than doubled median survival in PTEN-deficient colorectal cancer animal models while demonstrating a favorable toxicity profile. These results suggest potential for ONC010 in treating cancers with PTEN mutations, which are common in various tumor types.
The DDR inhibitor market is rapidly expanding, with new drug classes emerging. Onco-Innovations is leveraging its proprietary SynoGraph causal AI platform through subsidiary Inka Health to support manufacturing scale-up, IND-enabling studies, and planned first-in-human clinical development. The company's progress includes advancing ONC010 toward clinical trials, aiming to address unmet needs in oncology.
The editorial also reviewed recent developments across the oncology sector involving companies such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD), and Foghorn Therapeutics Inc. (NASDAQ: FHTX), highlighting the growing interest in DDR-based therapies. Onco-Innovations' focus on PNKP inhibition represents a differentiated approach that could offer new treatment options for patients with tumors resistant to existing therapies.
The full press release is available at https://ibn.fm/HH1VP. For more information on Onco-Innovations, visit the company's newsroom at https://ibn.fm/ONNVF.
